Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) insider David M. Spencer sold 2,500 shares of the business’s stock in a transaction on Tuesday, September 20th. The stock was sold at an average price of $20.01, for a total value of $50,025.00. Following the transaction, the insider now owns 173,382 shares in the company, valued at $3,469,373.82. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

David M. Spencer also recently made the following trade(s):

  • On Wednesday, July 27th, David M. Spencer sold 10,000 shares of Bellicum Pharmacueticals stock. The stock was sold at an average price of $15.00, for a total value of $150,000.00.

Shares of Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) opened at 19.71 on Wednesday. Bellicum Pharmacueticals Inc. has a 12 month low of $7.24 and a 12 month high of $23.84. The firm’s market cap is $533.12 million. The firm’s 50-day moving average price is $18.26 and its 200-day moving average price is $13.14.

Bellicum Pharmacueticals (NASDAQ:BLCM) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by $0.04. Bellicum Pharmacueticals had a negative return on equity of 42.22% and a negative net margin of 21,774.65%. During the same period last year, the firm earned ($0.40) EPS. Analysts expect that Bellicum Pharmacueticals Inc. will post ($2.34) earnings per share for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BLCM. ProShare Advisors LLC boosted its position in Bellicum Pharmacueticals by 10.6% in the second quarter. ProShare Advisors LLC now owns 22,654 shares of the biopharmaceutical company’s stock worth $294,000 after buying an additional 2,163 shares during the period. Geode Capital Management LLC boosted its position in Bellicum Pharmacueticals by 4.0% in the first quarter. Geode Capital Management LLC now owns 64,665 shares of the biopharmaceutical company’s stock worth $604,000 after buying an additional 2,513 shares during the period. BlackRock Group LTD boosted its position in Bellicum Pharmacueticals by 27.9% in the first quarter. BlackRock Group LTD now owns 12,443 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 2,713 shares during the period. Alliancebernstein L.P. boosted its position in Bellicum Pharmacueticals by 24.4% in the second quarter. Alliancebernstein L.P. now owns 19,400 shares of the biopharmaceutical company’s stock worth $251,000 after buying an additional 3,800 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Bellicum Pharmacueticals by 3.9% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 104,509 shares of the biopharmaceutical company’s stock worth $1,354,000 after buying an additional 3,888 shares during the period. Institutional investors own 65.24% of the company’s stock.

Several brokerages recently weighed in on BLCM. Piper Jaffray Cos. restated an “overweight” rating and set a $31.00 target price (up from $25.00) on shares of Bellicum Pharmacueticals in a research note on Tuesday, August 9th. Zacks Investment Research downgraded Bellicum Pharmacueticals from a “hold” rating to a “sell” rating in a research note on Thursday, August 11th. Jefferies Group restated a “buy” rating on shares of Bellicum Pharmacueticals in a research note on Tuesday, August 23rd. Citigroup Inc. upgraded Bellicum Pharmacueticals from a “neutral” rating to a “buy” rating and set a $24.00 target price on the stock in a research note on Tuesday, August 9th. Finally, SunTrust Banks Inc. began coverage on Bellicum Pharmacueticals in a research note on Thursday, June 2nd. They set a “buy” rating and a $20.00 target price on the stock. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Bellicum Pharmacueticals has an average rating of “Buy” and a consensus target price of $24.25.

Bellicum Pharmacueticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

5 Day Chart for NASDAQ:BLCM

Receive News & Ratings for Bellicum Pharmacueticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmacueticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.